1. |
Debate over use of albumin in the critically ill |
|
Inpharma Weekly,
Volume &NA;,
Issue 1149,
1998,
Page 2-2
&NA;,
Preview
|
PDF (854KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
2. |
Better quality trials needed in systemic sclerosis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1149,
1998,
Page 3-3
&NA;,
Preview
|
PDF (725KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
3. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1149,
1998,
Page 4-4
&NA;,
Preview
|
PDF (737KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
4. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1149,
1998,
Page 5-5
&NA;,
Preview
|
PDF (741KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
5. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1149,
1998,
Page 6-6
&NA;,
Preview
|
PDF (817KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
6. |
A rosy future for rosiglitazone in type 2 diabetes mellitus? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1149,
1998,
Page 7-8
Charles Bankhead,
Preview
|
PDF (1539KB)
|
|
摘要:
The thiazolidinediones (TZDs) have emerged as a potentially important addition to the pharmacological armamentarium for patients with type 2 diabetes mellitus. As a class, these agents directly target insulin resistance, while having no direct effect on the insulin-producing &bgr;-cells of the pancreas. Troglitazone, the prototype for this drug class, has proven efficacy in improving glycaemic control. However, it is associated with a 2% incidence of idiosyncratic elevation of liver enzyme levels, necessitating monitoring of liver function in treated patients. In contrast, the newer agent rosiglitazone [SmithKline Beecham; phase III] may offer increased potency for lowering blood glucose levels without affecting liver function, investigators said at the 58th Annual Meeting of the American Diabetes Association (ADA) [Chicago, US; June 1998].
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
7. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1149,
1998,
Page 8-8
&NA;,
Preview
|
PDF (751KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
8. |
&bgr;-Sheet breaker peptidespotential in Alzheimer's disease? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1149,
1998,
Page 9-9
&NA;,
Preview
|
PDF (695KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
9. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1149,
1998,
Page 10-10
&NA;,
Preview
|
PDF (780KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
10. |
Competition mounts but ‘Viagra’ stays on top |
|
Inpharma Weekly,
Volume &NA;,
Issue 1149,
1998,
Page 11-12
Charles Bankhead,
Preview
|
PDF (1547KB)
|
|
摘要:
The list of therapeutic options for male erectile dysfunction continues to expand. Notably, 2 new oral therapies have entered clinical trials. However, preliminary results suggest that neither phentolamine nor apomorphine pose an immediate threat to sildenafil's pre-eminent position as first-line therapy. Nevertheless, emergence of new agents will provide more options, especially for men who do not respond to sildenafil or for whom the agent is contraindicated. However, continued evaluation of intraurethral alprostadil has yielded disappointing results, as reported at the American Urological Association (AUA) meeting [San Diego, US; June 1998].
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|